Medical Oncology

, 34:177 | Cite as

Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis

  • Giuseppe Colloca
  • Antonella Venturino
  • Pasquale Vitucci
Review Article
  • 100 Downloads

Abstract

Neo-adjuvant chemo-radiation is the standard of care for patients with locally advanced rectal carcinoma. The aim of the present paper is to evaluate the relationship of the baseline serologic concentration of the carcinoembryonic antigen with the outcome. Data sources included MEDLINE and Web of Science databases. A systematic search of the databases by a predefined criterion has been conducted. Chemo-radiation followed by surgical resection of rectal tumors was the intervention of interest. From selected studies, the relationships between carcinoembryonic antigen and pathologic complete response, disease-free survival and overall survival were assessed. Carcinoembryonic antigen correlated significantly and inversely with the rate of pathologic complete responses (OR 2.00). Similar to this relationship, a low baseline carcinoembryonic antigen concentration was associated with a better disease-free survival (OR 1.88) and a better overall survival (OR 1.85). Heterogeneity of studies and publication bias were considerable in evaluating the relationship of baseline carcinoembryonic antigen and pathologic complete response. Baseline carcinoembryonic antigen should be regarded as a predictor of outcome of patients undergoing neo-adjuvant chemo-radiation. A calibration of the cutoff value from 5 to 3 ng/ml appears more appropriate to this patient population and should be evaluated in prospective trials.

Keywords

Carcinoembryonic antigen Rectal cancer Chemo-radiation Prognosis 

Notes

Compliance with ethical standards

Conflict of interest

None.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

References

  1. 1.
    Monson JRT, Weiser MR, Buie WD, Chang GJ, Rafferty JF. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum. 2013;56:535–50.CrossRefPubMedGoogle Scholar
  2. 2.
    Ferrari L, Fichera A. Neoadjuvant chemotadiation therapy and pathological complete response in rectal cancer. Gastroenterol Rep. 2015;3:277–88.Google Scholar
  3. 3.
    Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Brit J Surg. 2012;99:918–28.CrossRefPubMedGoogle Scholar
  4. 4.
    Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy. Ann Surg. 2004;240:711–8.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefPubMedGoogle Scholar
  6. 6.
    Methy N, Bedenne L, Conroy T, Bouchè O, Chapet O, Ducreux M, et al. Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. Ann Oncol. 2010;21:518–24.CrossRefPubMedGoogle Scholar
  7. 7.
    Garland ML, Vather R, Bunkley N, Pearse M, Bisset IP. Clinical tumor size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Int J Colorectal Dis. 2014;29:301–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Buijsen J, van Stiphout RG, Menheere PPCA, Lammering G, Lambin P. Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: a prospective, hypothesis driven study on patients with locally advanced rectal cancer. Radiother Oncol. 2014;111:237–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Sprenger T, Conradi L-C, Beissbarth T, Ermert H, Homayounfar K, Middel P, et al. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival. Cancer. 2013;119:26–35.CrossRefPubMedGoogle Scholar
  10. 10.
    Yasuda K, Sunami E, Kawai K, Nagawa H, Kitayama J. Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer. J Gastrointest Cancer. 2012;43:236–43.CrossRefPubMedGoogle Scholar
  11. 11.
    Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, et al. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci. 2014;105:996–1001.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Tabuchi Y, Deguchi H, Imanishi K, Saitoh Y. Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer. Cancer. 1987;59:1283–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15:3433–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Park Y-A, Sohn S-K, Seong J, Baik SH, Lee KY, Kim NK, et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol. 2006;93:145–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109:1750–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250:582–9.PubMedGoogle Scholar
  18. 18.
    Moreno Garcìa V, Cejas P, Blanco Codesido M, Feliu Batlle J, de Castro Carpeno J, Belda-Iniesta C, et al. Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 2009;24:741–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Park JW, Lim S-B, Kim DY, Jung KH, Hong YS, Chang HJ, et al. Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol Phys. 2009;74:810–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Perez RO, Sao Juliao GP, Habr-Gama A, Kiss D, Proscurshim I, Campos FG, et al. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum. 2009;52:1137–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, et al. Pathologic nodal classification is he most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Biol Phys. 2010;77:1158–65.CrossRefGoogle Scholar
  22. 22.
    Yoon WS, Park W, Choi DH, Ahn YC, Chun HK, Lee WY, et al. Importance of the circumferential extent of tumors and clinical lymph node status as prognostic factors after preoperative chemoradiotherapy and surgery in patients with rectal cancer. Tumori. 2010;96:568–76.PubMedGoogle Scholar
  23. 23.
    Jang NY, Kang SB, Kim DW, Kim JH, Lee KW, Kim IA, et al. The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. Dis Colon Rectum. 2011;54:245–52.CrossRefPubMedGoogle Scholar
  24. 24.
    Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, et al. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2011;18:3271–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Moureau-Zabotto L, Farnault B, de Chaisemartin C, Esterni B, Lelong B, Viret F, et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2011;80:483–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Topova L, Hellmich G, Puffer E, Schubert C, Christen N, Boldt T, et al. Prognostic value of tumor response to neoadjuvant therapy in rectal carcinoma. Dis Colon Rectum. 2011;54:401–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Song S, Hong JC, McDonnell SE, Koong AC, Minsky BD, Chang DT, et al. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol. 2012;19:2471–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Conde S, Borrego M, Teixeira T, Teixeira R, Sà A, Soares P. Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: prognostic factors. Rep Pract Oncol Radiother. 2013;18:67–75.CrossRefGoogle Scholar
  29. 29.
    Huh JW, Kim HR, Kim YJ. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum. 2013;56:698–703.CrossRefPubMedGoogle Scholar
  30. 30.
    Lee JH, Kim SH, Jang HS, Chung HJ, Oh ST, Lee DS, et al. Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population. Int J Colorectal Dis. 2013;28:511–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Restivo A, Zorcolo L, Cocco IM, Manunza R, Margiani C, Marongiu L, et al. Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann Surg Oncol. 2013;20:864–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A. CEA—A predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum. 2013;56:859–68.CrossRefPubMedGoogle Scholar
  33. 33.
    Yang KL, Yang SH, Liang WY, Kuo YJ, Lin JK, Lin TC, et al. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiation Oncol. 2013;8:43.CrossRefGoogle Scholar
  34. 34.
    Yeo SG, Kim DY, Chang HJ, Park JW, Oh JH, Kim BC, et al. Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy. Tumori. 2013;99:93–9.PubMedGoogle Scholar
  35. 35.
    Huang CS, Lin JK, Wang LW, Liang WY, Lin CC, Lan YT, et al. Assessment of the value of carcinoembryonic antigen reduction ratio as a prognostic factor in rectal cancer. Am J Surg. 2014;208:99–105.CrossRefPubMedGoogle Scholar
  36. 36.
    Armstrong D, Raissouni S, Price Hiller J, Mercer J, Powell E, MacLean A, et al. Predictors of pathologic complete response after neoadjuvant treatment for rectal cancer: a multicenter study. Clin Colorectal Cancer. 2015;14:291–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Bitterman DS, Salgado LS, Moore HG, Sanfilippo NJ, Gu P, Hatzaras I, et al. Predictors of complete response and disease recurrence following chemoradiation for rectal cancer. Front Oncol. 2015;5:286.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Engineer R, Basu T, Chopra S, Arya S, Patil P, Mehta S, et al. Factors influencing response to neoadjuvant chemoradiation and outcomes in rectal cancer patients: tertiary Indian cancer hospital experience. J Gastrointest Oncol. 2015;6:155–64.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Kim CH, Lee SY, Kim HR, Kim YJ. Prognostic effect of pretreatment serum carcinoembryonic antigen level. Medicine. 2015;94:e1291.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Kleiman A, Al-Khamis A, Farsi A, Kezouh A, Vuong T, Gordon PH, et al. Normalization of CEA levels post-neoadjuvant therapy is a strong predictor of pathologic response in rectal cancer. J Gastrointest Surg. 2015;19:1106–12.CrossRefPubMedGoogle Scholar
  41. 41.
    Lee JH, Kim DY, Kim SH, Cho HM, Shim BY, Kim TH, et al. Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: a multi-institutional and case-matched control study of KROG 14-12. Radiother Oncol. 2015;116:202–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Yoon WH, Kim HJ, Kim CH, Joo JK, Kim YJ, Kim HR. Oncologic impact of pathologic response on clinical outcome after preoperative chemoradiotherapy in locally advanced rectal cancer. Ann Surg Treat Res. 2015;88:15–20.CrossRefPubMedGoogle Scholar
  43. 43.
    Zeng WG, Liang JW, Wang Z, Zhang XM, Hu JJ, Hou HR, et al. Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Chin J Cancer. 2015;34:41.CrossRefPubMedCentralGoogle Scholar
  44. 44.
    Chung MJ, Nam TK, Jeong JU, Kim SH, Kim K, Jang HS, et al. Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study. Int J Colorectal Dis. 2016;31:1595–601.CrossRefPubMedGoogle Scholar
  45. 45.
    Song JH, Kim SH, Lee JH, Cho HM, Kim DY, Kim TH, et al. Significance of histologic tumor grade in rectal cancer treated with preoperative chemoradiotherapy followed by curative surgery: a multi-institutional retrospective study. Radiother Oncol. 2016;118:387–92.CrossRefPubMedGoogle Scholar
  46. 46.
    Sung SY, Son SH, Kay CS, Lee YS. Prognosis can be predicted more accurately using pre- and postchemoradiotherapy carcinoembryonic antigen levels compared to only prechemoradiotherapy carcinoembryonic antigen level in locally advanced rectal cancer patients who received neoadjuvant chemoradiotherapy. Medicine. 2016;95:e2965.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Bonnetain F, Bossett JF, Gerard JP, Calais G, Conroy T, Mineur L, et al. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? Eur J Cancer. 2012;48:1781–90.CrossRefPubMedGoogle Scholar
  48. 48.
    Yeo SG. Association of pretreatment serum carcinoembryonic antigen levels with chemoradiation-induced downstaging and downsizing of rectal cancer. Mol Clin Oncol. 2016;4:631–5.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Bettoni F, Masotti C, Habr-Gama A, Correa BR, Gama-Rodrigues J, Vianna MR, et al. Intratumoral genetic heterogeneity in rectal cancer. Ann Surg. 2017;265:e4–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Hetch M, Buttner-Herold M, Erlenbach-Wunsch K, Haderlein M, Croner R, Grutzmann R, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016;65:52–60.CrossRefGoogle Scholar
  51. 51.
    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, et al. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol. 2000;30:12–6.CrossRefPubMedGoogle Scholar
  53. 53.
    Peng Y, Wang L, Gu J. Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer. World J Surg. 2013;37:208–13.CrossRefPubMedGoogle Scholar
  54. 54.
    Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst. 2011;103:689–97.CrossRefPubMedGoogle Scholar
  55. 55.
    Bufalari A, Boselli C, Giustozzi G, Moggi L. Locally advanced rectal cancer: a multivariate analysis of outcome risk factors. J Surg Oncol. 2000;74:2–10.CrossRefPubMedGoogle Scholar
  56. 56.
    Tarantino I, Warschkow R, Schmied BM, Guller U, Mieth M, Cerny T, et al. Predictive value of CEA for survival in stage I rectal cancer: a population-based propensity score-matched analysis. J Gastrointest Surg. 2016;20:1213–22.CrossRefPubMedGoogle Scholar
  57. 57.
    Nagtegaal ID, Gosens MJEM. Combinations of tumor and treatment parameters are more discriminative for prognosis than the present TNM system in rectal cancer. J Clin Oncol. 2007;25:1647–50.CrossRefPubMedGoogle Scholar
  58. 58.
    Lou Z, Meng RG, Zhang W, Yu ED, Fu CG. Preoperative carcinoembryonic antibody is predictive of distant metastasis in pathologically T1 colorectal cancer after radical surgery. World J Gastroenterol. 2013;19:389–93.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Amri R, Bordeianou LG, Sylla P, Berger DL. Preoperative carcinoembryonic antigen as an outcome predictor in colon cancer. J Surg Oncol. 2013;108:14–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Bramswig KH, Poettler M, Unseld M, Wrba F, Uhrin P, Zimmermann W, et al. Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res. 2013;73:6584–96.CrossRefPubMedGoogle Scholar
  61. 61.
    Ordonez C, Zhai AB, Camacho-Leal P, Demarte L, Fan MMY, Stanners CP. GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin α5β1-fibronectin interaction. J Cell Physiol. 2007;210:757–65.CrossRefPubMedGoogle Scholar
  62. 62.
    Tibetts LM, Doremus CM, Tzanakakis GN, Vezeridis MP. Liver metastases with 10 human colon carcinoma cell lines in nude mice and association with carcinoembryonic antigen production. Cancer. 1993;71:315–21.CrossRefGoogle Scholar
  63. 63.
    Bramswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, Szalai K, et al. Immunization with mimotopes prevents growth of carcinoembryonic antigen-positive tumors in BALB/c mice. Clin Cancer Res. 2007;13:6501–8.CrossRefPubMedGoogle Scholar
  64. 64.
    Chan CH, Camacho-Lea P, Stanners CP. Colorectal hyperplasia and dysplasia due to human carcinoembryonic antigen (CEA) family member expression in transgenic mice. PLoS ONE. 2007;2:e1353.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of Oncology, G. Borea HospitalSanremoItaly
  2. 2.Department of RadiotherapyOspedali RiunitiAnconaItaly

Personalised recommendations